Cargando…
Pharmacologic effects of naldemedine, a peripherally acting μ‐opioid receptor antagonist, in in vitro and in vivo models of opioid‐induced constipation
BACKGROUND: Naldemedine (S‐297995) is a peripherally acting μ‐opioid receptor antagonist developed as a once‐daily oral drug for opioid‐induced constipation (OIC) in adults with chronic noncancer or cancer pain. This study characterized the pharmacological effects of naldemedine in vitro and in vivo...
Autores principales: | Kanemasa, Toshiyuki, Koike, Katsumi, Arai, Tohko, Ono, Hiroko, Horita, Narumi, Chiba, Hiroki, Nakamura, Atsushi, Morioka, Yasuhide, Kihara, Tsuyoshi, Hasegawa, Minoru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850587/ https://www.ncbi.nlm.nih.gov/pubmed/30821019 http://dx.doi.org/10.1111/nmo.13563 |
Ejemplares similares
-
Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022) -
A retrospective study of the efficacy and safety of naldemedine for opioid‐induced constipation in thoracic cancer patients
por: Imai, Hisao, et al.
Publicado: (2022) -
Real-World Evidence for the Safety and Effectiveness of Naldemedine in the Management of Opioid-Induced Constipation in Patients With Cancer Pain: Post-hoc Subgroup Analysis of Post-marketing Surveillance in Japan
por: Naya, Noriyuki, et al.
Publicado: (2023) -
Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018) -
A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer
por: Kamiya, Teruhiko, et al.
Publicado: (2023)